AAV9-mediated MUC1 gene therapy

AAV9-mediated MUC1 gene therapy has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 8, 2026: “Restoring a cell-surface protein eased lung disease in mice”.

Intervention

1 paper studies it1 findingUpdated

1 new paper in 30 daysSee all 1 papers on AAV9-mediated MUC1 gene therapy

At a glance

The findings reach mice, none yet in people. 1 lab.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab
  • Animals1

What did studies of AAV9-mediated MUC1 gene therapy find?

1

Studies of AAV9-mediated MUC1 gene therapy measured 1 outcome; the most studied are chronic obstructive pulmonary disease severity (1 study).

Chronic obstructive pulmonary disease severity

downin mice1

1 study
  1. AAV9-mediated MUC1 gene therapy decreases chronic obstructive pulmonary disease severity in mice (cigarette smoke-induced COPD).

    “Adeno-associated virus serotype 9 (AAV9)-mediated AT2 cell-specific reconstitution of Muc1 ameliorated COPD”

    Animalscigarette smoke-induced COPDAAV9-mediated AT2 cell-specific reconstitutionlung

    Restoring a cell-surface protein eased lung disease in mice

    Signal transduction and targeted therapy

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months
Signal Transduction and Targeted Therapy

Restoring a cell-surface protein eased lung disease in mice

In experiments involving 24 weeks of cigarette smoke exposure, mice lacking the protein had faster lung-function decline and more inflammation than their normal…In experiments involving 24 weeks of cigarette smoke exposure, mice lacking the protein had faster lung-function decline and more inflammation than their normal littermates.

Mouse studyLung